|
Apr 10
|
Kura Oncology to Participate in Stifel Targeted Oncology Forum
|
|
Mar 6
|
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
|
|
Feb 2
|
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 1
|
Chief Medical Officer Stephen Dale Sells Shares of Kura Oncology Inc
|
|
Jan 30
|
Kura Makes Good On Its $150 Million Infusion And Shoots Up 12%
|
|
Jan 30
|
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
|
|
Dec 8
|
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
|
|
Nov 28
|
Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
|
|
Nov 5
|
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Kura Oncology Inc (KURA) Reports Q3 2023 Financial Results
|
|
Nov 2
|
Kura Oncology Reports Third Quarter 2023 Financial Results
|
|
Nov 2
|
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
|